At a glance
ClinicalIndex Comparison RecordN/ACompleted· 101 enrolled
Drug / intervention
CardioFlux Magnetocardiographyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of the Cardioflux Magnetocardiography System in Predicting Patient Outcomes With Coronary Artery Disease
In Brief
An observational study evaluating CardioFlux Magnetocardiography for Coronary Artery Disease. Completed, enrolled 101 participants across 1 site.
Detailed Summary
This single-center clinical trial is designed to evaluate the CardioFlux magnetocardiograph diagnostic imaging system to predict major adverse cardiac events (MACE) in patients referred for evaluation for coronary artery disease.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartSep 2019
Primary CompletionJun 2020
TodayJul 2026
First PostedMay 30, 2019
Enrollment StartSep 5, 2019
Primary CompletionJun 20, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.1 years ago
Interventions
CardioFlux Magnetocardiographyother
All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.